Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Expands By 621.9%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) saw a large increase in short interest in January. As of January 15th, there was short interest totaling 2,541 shares, an increase of 621.9% from the December 31st total of 352 shares. Based on an average daily volume of 25,320 shares, the short-interest ratio is presently 0.1 days. Approximately 0.2% of the shares of the stock are short sold. Approximately 0.2% of the shares of the stock are short sold. Based on an average daily volume of 25,320 shares, the short-interest ratio is presently 0.1 days.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Zacks Research cut shares of Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 20th. HC Wainwright set a $7.00 price target on shares of Bolt Biotherapeutics and gave the company a “buy” rating in a report on Monday, October 20th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $34.00.

Institutional Investors Weigh In On Bolt Biotherapeutics

Institutional investors have recently modified their holdings of the stock. Squarepoint Ops LLC increased its position in shares of Bolt Biotherapeutics by 19.8% during the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after purchasing an additional 2,448 shares during the last quarter. Shay Capital LLC purchased a new position in Bolt Biotherapeutics during the third quarter worth $85,000. Finally, Susquehanna International Group LLP bought a new position in Bolt Biotherapeutics during the third quarter valued at $89,000. 86.70% of the stock is owned by institutional investors.

Bolt Biotherapeutics Price Performance

Bolt Biotherapeutics stock opened at $7.09 on Wednesday. The company has a market cap of $13.61 million, a price-to-earnings ratio of -0.32 and a beta of 0.91. The firm’s fifty day moving average is $5.60 and its 200 day moving average is $5.51. The company has a quick ratio of 3.57, a current ratio of 3.57 and a debt-to-equity ratio of 0.65. Bolt Biotherapeutics has a 52-week low of $4.41 and a 52-week high of $10.50.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its earnings results on Wednesday, November 12th. The company reported ($3.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($5.07) by $1.35. The business had revenue of $2.17 million during the quarter, compared to the consensus estimate of $0.82 million. Sell-side analysts forecast that Bolt Biotherapeutics will post -1.61 EPS for the current fiscal year.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.